Vastec Medical
Leading the Next Generation of In-Vitro Diagnostics

As the global healthcare industry moves toward faster, more accurate and cost-effective diagnostics, China’s in-vitro diagnostic (IVD) market is undergoing a profound transformation. Leading this evolution is Vastec Medical, a Hong Kong-based company that has become a key force in advancing diagnostic capabilities across the country.

Founded in 1993, Vastec Medical has built a reputation for delivering state-of-the-art IVD solutions that enhance clinical precision, operational efficiency, and patient accessibility. The company specializes in haemostasis, molecular diagnostics, and clinical chemistry—three areas critical to early detection and effective treatment planning.

What sets Vastec apart is its commitment to integrating the latest scientific developments into practical, real-world applications. By continuously evolving its technology portfolio, the company equips healthcare providers with faster and more reliable diagnostic tools, enabling improved patient outcomes and setting new benchmarks in medical testing.

Expanding Reach through a Robust Distribution Network

A key driver of Vastec Medical’s success is its extensive, multi-level distribution network, ensuring widespread access to advanced diagnostic solutions. The company reaches 1,599 Class III hospitals through a network of 1,139 distributors spanning 31 provinces, municipalities, and autonomous regions.

Vastec Medical’s long-standing partnership with Sysmex is a major force behind this reach. Since 1997, the company has held exclusive national distribution rights for Sysmex haemostasis products in China. As a renowned IVD supplier, Sysmex leads China’s haemostasis analysis market, holding a 40.8 percent market share and a 74.0 percent penetration rate among the country’s top 100 hospitals. This partnership reinforces the company’s leadership in clinical diagnostics and strengthens its nationwide healthcare impact.

Driving Innovation through Strategic Partnerships

Beyond distribution, Vastec Medical is committed to developing advanced diagnostic solutions. In December 2019, the company launched the IVD Ecosphere project, uniting leading local IVD manufacturers with independent intellectual property rights and renowned foreign manufacturers in non-haemostasis IVD products. This initiative enhances product accessibility and integration, expanding China’s diagnostic capabilities.

Today, the IVD Ecosphere portfolio spans all six major IVD categories, featuring 500+ products from 18 local IVD manufacturers. Their analyzers are widely deployed in major hospitals across mainland China.

“By investing in technology and strategic partnerships, we continue to expand our capabilities, ensuring that innovative diagnostic solutions reach hospitals and laboratories across China efficiently,” says K.S Ho, CEO at Vastec Medical.

Further advancing its technological leadership, Vastec Medical entered the mass spectrometry field by acquiring Bazoe, a local IVD R&D and manufacturing company with independent IP rights for reagents. Bazoe’s portfolio includes 40+ registered products and 15 patents, making it a leader in molecular analysis and a key contributor to disease detection and monitoring advancements.

The company has strengthened its microbiology diagnostics segment through the acquisition of Langmai. Additionally, Vastec Medical plays a pivotal role in molecular diagnostics, shaping the future of personalized medicine and infectious disease management.

Its joint venture with ICX IVD, a specialized IVD R&D and manufacturing company, is a critical enabler of this progress. This collaboration enhances high-sensitivity molecular diagnostics, supporting qPCR-based pathogen detection and advanced genetic sequencing (NGS and temNGS).

Expanding Brand Presence in China

Vastec Medical’s comprehensive infrastructure integrates distribution, research, and after-sales service. Its strong supply chain ensures fast, reliable hospital deliveries, while dedicated research teams drive continuous innovation. By investing in proprietary technology— particularly in mass spectrometry, microbiology automation, and molecular diagnostics—the company remains a leader in China’s IVD industry.

Strategic co-operation with Shimadzu, Thermo Fisher, Alifax, CellaVision, and Tecan further reinforce its expertise in mass spectrometry, molecular diagnostics, clinical microbiology, digital morphology, and automated liquid handling.

For healthcare institutions and diagnostic manufacturers looking to expand into China, Vastec Medical offers a proven platform for product development, distribution, and integration. By attracting a diverse range of IVD products through strategic brand partnerships, the company strengthens its competitive edge in centralized procurement.

In addition, the company actively participates in national and local IVD seminars and academic conferences to enhance brand visibility. These efforts ensure that Vastec Medical remains at the forefront of diagnostic innovation, delivering solutions that shape the future of healthcare.